Stalicla SA announced the first close of a series B round at $17.4 million, which provides the means to complete preparations for both a phase III trial of the lead program, STP-7, in the treatment of cocaine misuse disorder, and of a phase II trial of STP-1 in autism spectrum disorder (ASD).

Biopharmas raising money in public or private financings, including: Bridgebio, CG, Immatics, Mirae, Viridian.

Kyverna Therapeutics Inc. disclosed a filing to raise up to $100 million in an IPO, becoming the sixth firm to announce plans for a U.S. listing in the new year, offering tentative hope that the public markets might prove more welcoming to biopharma firms after a lackluster 2023.

Biopharmas raising money in public or private financings, including: Anacardio, Bolden, Bristol Myers Squibb, Cellectis, Clearmind, Comanche, Ratio, Tr1x, Utility.

Biopharmas raising money in public or private financings, including: Alto, Cyrano, Defence, Delsitech, Disco, Prota, Stalicla, Vaxart, Xortx.

Biopharmas raising money in public or private financings, including: Dyne.

Biopharmas raising money in public or private financings, including: Clearmind, Inventiva, Nodus, Praxis.

Biopharmas raising money in public or private financings, including: Bolden, Catalyst, Maps, Mimivax, Myrobalan, Opko.

Biopharmas raising money in public or private financings, including: Acousia, Biosenic, Jixing, Keros, Kymera, Longboard, Zealand.